According to OPKO Health 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6. At the end of 2021 the company had a P/E ratio of -96.2.
Year | P/E ratio | Change |
---|---|---|
2021 | -96.2 | -221.77% |
2020 | 79.0 | -2948.3% |
2019 | -2.77 | -75.12% |
2018 | -11.1 | 25.13% |
2017 | -8.91 | -96.17% |
2016 | -233 | 101.42% |
2015 | -115 | 362.19% |
2014 | -25.0 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 32.3 | -638.02% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 29.8 | -596.51% | ๐บ๐ธ USA |
![]() Regeneron Pharmaceuticals REGN | 20.5 | -442.06% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 15.6 | -359.70% | ๐บ๐ธ USA |
![]() LabCorp LH | 22.0 | -467.26% | ๐บ๐ธ USA |
![]() Alnylam Pharmaceuticals
ALNY | -19.9 | 232.08% | ๐บ๐ธ USA |
![]() Teva Pharmaceutical Industries TEVA | -5.18 | -13.75% | ๐ฎ๐ฑ Israel |
![]() Ardelyx ARDX | -13.6 | 127.01% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.